表皮生长因子受体抑制剂引起的皮肤毒性：诊断与处理  

Dermatological toxicities to EGFR inhibitors:Diagnosis and management

作　　者：陈振东[1] 卜丽佳[1] 吴秀伟[1] 杜瀛瀛[1] 

机构地区：[1]安徽医科大学第一附属医院肿瘤内科,合肥230022

出　　处：《癌症进展》2007年第6期567-571,共5页Oncology Progress

摘　　要：分子靶向抗癌药物的毒副作用迥然不同于传统的细胞毒药物,尤其是其最为常见的皮肤毒性,可引发身体和心理的明显异常,导致药物的减量或中断从而影响治疗的效果。了解这些皮肤毒性的机制,制定适当的毒性分期标准,进而给予正确的防治,对确保患者生活质量及抗肿瘤治疗的连续性都十分重要。本文综述分子靶向抗癌药物中最有代表性的表皮生长因子受体抑制剂的皮肤毒副作用的发生率、临床表现、发病机制以及诊断和处理原则。Unlike standard chemotherapy, treatment with the molecular targeted anti -tumor agents is associated with an increased incidence of dermatological toxicities. The resulted significant physical and psycho-social discomfort may lead to interruption or dose modification of the molecular targeted anti - tumor agents. It is urgent and important for further understanding of these toxicities to develop adequate staging systems and mechanistically driven therapies, in which the quality of life and consistent antineoplastic therapy can be ensured. In this article, the authors reviewed the dermatological toxicities of EGFRIs, a typical molecular targeted anti-tumor agents, as well as its incidence, clinical situation, pathogenesis, principle of diagnosis, and management.

关 键 词：分子靶向抗癌药物 表皮生长因子受体抑制剂 皮肤毒性 

分 类 号：R730.54[医药卫生—肿瘤]